Detalhe da pesquisa
1.
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Cancer Med
; 13(3): e7003, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400682
2.
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Leuk Res
; 136: 107437, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215555
3.
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Leuk Lymphoma
; 63(6): 1398-1406, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35634787
4.
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.
Cancers (Basel)
; 12(8)2020 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32722211
5.
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome.
Blood Adv
; 4(16): 3840-3849, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32790847
6.
Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders.
Hemasphere
; 7(3): e847, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36844177
7.
Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases.
Leuk Lymphoma
; 63(1): 250-252, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474632
8.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Blood Cancer J
; 11(11): 180, 2021 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775463